Search for Clinical Trial Results

Sponsored By

Carcinoma, Transitional Cell - 25 Studies Found

Status Study
Completed Study Name: The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma
Condition: Carcinoma, Transitional Cell
Date: 2010-08-25
Recruiting Study Name: A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection [IMvigor010]
Condition: Carcinoma, Transitional Cell
Date: 2015-05-19
Interventions: Drug: Atezolizumab Atezolizumab will be administered at a dose of 1200 milligrams (mg).
Not yet recruiting Study Name: Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract
Condition: Carcinoma, Transitional Cell
Date: 2017-02-09
Interventions:
  • Drug: nanoparticle albumin-bound paclitaxel, S-1

Withdrawn Study Name: Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
Condition: Urothelial Carcinoma
Date: 2010-02-18
Interventions:
  • Drug: Docetaxel Docetaxel IV 7
Withdrawn Study Name: BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
Condition: Urothelial Carcinoma
Date: 2014-10-28
Interventions: Drug: BIBF1120 BIBF1120 200 mg two times per day orally
Completed Study Name: 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
Condition:
  • Urologic Neoplasms
  • Carcinoma, Transitional Cell

Date: 2005-09-12
Interventions: Drug: Gemcitabine
Withdrawn Study Name: Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
Condition: Urothelial Carcinoma
Date: 2013-07-16
Interventions:
  • Drug: AMG 386 Patients will re
Withdrawn Study Name: Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma
Condition: Carcinoma, Transitional Cell
Date: 2005-09-12
Interventions: Drug: Lycopene
Recruiting Study Name: A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma
Condition: Urothelial Carcinoma
Date: 2016-08-16
Interventions: Drug: INCB054828 INCB054828 once daily on a 2-weeks-on-therapy and 1-week-off-therapy schedule
Completed Study Name: Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma
Condition: Urothelial Carcinoma
Date: 2012-05-23
Interventions: Drug: Valrubicin Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days
Next >>>